Claims for Patent: 8,129,145

Summary for Patent: 8,129,145

Title:	Production of glycoproteins
Abstract:	An improved system for large scale production of glycoproteins in cell culture is provided. In accordance with the present invention, cells expressing a glycoprotein are grown in media that contain manganese at a concentration of between approximately 10 and 600 nM. The use of such a system allows production of a glycoprotein with an increased glycosylation pattern and/or a glycosylation pattern that more accurately reflects the glycosylation pattern of the naturally occurring glycoprotein. A glycoprotein expressed in accordance with the present invention may be advantageously used in the preparation of pharmaceutical compositions.
Inventor(s):	Lasko; Daniel R. (Medford, MA), Koza; Stephan M. (Newbury, MA)
Assignee:	Wyeth LLC (Madison, NJ)
Application Number:	11/827,301
Patent Claims:	1. A method of producing a glycoprotein in a cell culture comprising: culturing mammalian cells that contain a gene encoding a glycoprotein of interest in a cell culture medium comprising between approximately 10 nM and 600 nM manganese, wherein the glycoprotein of interest comprises O-linked oligosaccharide chains; maintaining the culture at a first temperature range of about 30 to 42 degrees Celsius for a first period of time sufficient to allow the cells to reproduce to a viable cell density within a range of about 20%-80% of the maximal possible viable cell density if the culture were maintained at the first temperature range; and shifting the culture to a second temperature range and maintaining the culture for a second period of time sufficient to permit expression of the glycoprotein, wherein the second temperature range comprises a temperature range that is approximately 25 to 41 degrees Celsius, wherein the glycosylation pattern of the expressed glycoprotein is more extensive than the glycosylation pattern observed under otherwise identical conditions in otherwise identical medium that lacks the manganese. 2. The method of claim 1, wherein the first temperature range comprises a temperature that is approximately 37 degrees Celsius. 3. The method of claim 1, wherein the second temperature range comprises a temperature that is approximately 31 degrees Celsius. 4. The method of claim 1, wherein the cell culture medium comprises between approximately 20 and 200 nM manganese. 5. The method of claim 4, wherein the cell culture medium comprises approximately 40 nM manganese. 6. The method of claim 1, wherein the cell culture medium comprises glutamine at an initial concentration which is less than or equal to approximately 8 mM. 7. The method of claim 6, wherein the initial glutamine concentration of the cell culture medium is less than or equal to approximately 4 mM. 8. The method of claim 1, wherein the volume of the cell culture is about 500 L. 9. The method of claim 1, wherein the cell culture is further provided with a feed medium after the initial cell culture is begun. 10. The method of claim 1, wherein the cell culture is further provided with supplementary components. 11. The method of claim 10 wherein the supplementary components are selected from the group consisting of hormones and/or other growth factors, inorganic ions, buffers, vitamins, nucleosides or nucleotides, trace elements, amino acids, lipids, glucose or other energy sources, and combinations thereof. 12. The method of claim 11, wherein the cell culture is supplemented with approximately 2 grams per liter glucose. 13. The method of claim 1, wherein the cell culture medium is defined. 14. The method of claim 1, wherein the glycoprotein of interest comprises coagulation factor IX. 15. The method of claim 14, wherein the coagulation factor IX is recombinant human coagulation Factor IX. 16. A method of producing a glycoprotein in a cell culture comprising steps of: culturing mammalian cells that contain a gene encoding coagulation Factor IX (FIX) as a glycoprotein of interest in a cell culture medium comprising approximately 40 nM manganese under conditions and for a time sufficient to permit expression of the FIX glycoprotein, wherein the glycosylation pattern of the expressed FIX glycoprotein is more extensive at 40 nM manganese than the FIX glycosylation pattern observed at other manganese levels under otherwise identical conditions in otherwise identical medium. 17. A method of producing a glycoprotein in a cell culture comprising steps of: culturing mammalian cells that contain a gene encoding coagulation Factor IX (FIX) as a glycoprotein of interest in a cell culture medium comprising 10 nM-600 nM manganese under conditions and for a time sufficient to permit expression of the FIX glycoprotein, wherein the glycosylation pattern of the expressed FIX glycoprotein is more extensive at 10 nM-600 nM manganese than the FIX glycosylation pattern observed at other manganese levels under otherwise identical conditions in otherwise identical medium. 18. A method of producing a glycoprotein in a cell culture comprising: culturing mammalian cells that contain a gene encoding a glycoprotein of interest in a cell culture medium comprising between approximately 10 nM and 600 nM manganese, wherein the cell culture medium comprises glutamine at an initial concentration which is less than or equal to approximately 8 mM, and wherein the glycoprotein of interest comprises O-linked oligosaccharide chains; maintaining the culture at a first temperature range of about 30 to 42 degrees Celsius for a first period of time sufficient to allow the cells to reproduce to a viable cell density within a range of about 20%-80% of the maximal possible viable cell density if the culture were maintained at the first temperature range; and maintaining the culture for a second period of time sufficient to permit expression of the glycoprotein, wherein the glycosylation pattern of the expressed glycoprotein is more extensive than the glycosylation pattern observed under otherwise identical conditions in otherwise identical medium that lacks the manganese.

Details for Patent 8,129,145

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Wyeth Pharmaceuticals Llc	BENEFIX	coagulation factor ix (recombinant)	For Injection	103677	February 11, 1997	8,129,145	2026-07-13
Wyeth Pharmaceuticals Llc	BENEFIX	coagulation factor ix (recombinant)	For Injection	103677	March 21, 2007	8,129,145	2026-07-13
Wyeth Pharmaceuticals Llc	BENEFIX	coagulation factor ix (recombinant)	For Injection	103677	November 23, 2011	8,129,145	2026-07-13
Medexus Pharma, Inc.	IXINITY	coagulation factor ix (recombinant)	For Injection	125426	April 29, 2015	8,129,145	2026-07-13
Medexus Pharma, Inc.	IXINITY	coagulation factor ix (recombinant)	For Injection	125426	December 21, 2015	8,129,145	2026-07-13
Takeda Pharmaceuticals U.s.a., Inc.	RIXUBIS	coagulation factor ix (recombinant)	For Injection	125446	June 26, 2013	8,129,145	2026-07-13